https://scholars.lib.ntu.edu.tw/handle/123456789/629338
標題: | Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience | 作者: | Lin, Li-Ching Huang, Wen-Kuan Yen, Chueh-Chuan CHING-YAO YANG Sung, Meng-Ta Wong, Natalie S.M. Chua, Daniel T T Lee, Sarah W M Chen, Jen-Shi Yeh, Chun-Nan |
關鍵字: | GIST; advanced; compassionate use; metastatic; ripretinib | 公開日期: | 2022 | 出版社: | FRONTIERS MEDIA SA | 卷: | 12 | 來源出版物: | Frontiers in oncology | 摘要: | Ripretinib was recently approved for the fourth-line targeted therapy for advanced gastrointestinal stromal tumor (GIST) refractory to imatinib, sunitinib, and regorafenib based on the pivotal INVICTUS phase III study. The INVICTUS study demonstrated significantly improved median progression-free survival (PFS) of 6.3 months and an overall survival (OS) insignificant benefit of ripretinib of 15.1 months as compared with placebo in 85 patients with advanced metastatic GIST. However, treatment outcome for the Chinese population, including in Taiwan and Hong Kong, was lacking. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/629338 | ISSN: | 2234-943X | DOI: | 10.3389/fonc.2022.883399 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。